Anzeige
Mehr »
Login
Dienstag, 25.03.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Gold-Highflyer startet durch - Mega-Bohrprogramm sorgt für Kursfantasie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7QK | ISIN: GB0034330679 | Ticker-Symbol: DWV
Frankfurt
25.03.25
08:17 Uhr
0,106 Euro
+0,019
+21,14 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ANGLE PLC Chart 1 Jahr
5-Tage-Chart
ANGLE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,1060,11515:39

Aktuelle News zur ANGLE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrAngle completes assay development projects1
FrAngle PLC grants new share options to staff and directors8
FrAngle PLC gewährt Mitarbeitern und Direktoren neue Aktienoptionen2
FrAngle PLC Announces Results of Eisai Phase 2 pilot study171UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay...
► Artikel lesen
FrAngle PLC Announces Issue of LTIP Options and Share Options118GUILDFORD, SURREY / ACCESS Newswire / March 21, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders...
► Artikel lesen
29.01.Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay273NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platformFindings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single...
► Artikel lesen
24.01.Angle's Parsortix system used in 'breakthrough' breast cancer research1
24.01.Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich242CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatmentParsortix system used to identify patients with highly metastatic CTC clusters for targeted...
► Artikel lesen
ANGLE Aktie jetzt für 0€ handeln
23.01.Broker tips: Spectris, Inchcape, AutoTrader, JD Sports, Angle8
23.01.Angle fails to win market confidence despite narrowing loss in 20242
23.01.Berenberg slashes target price on Angle3
23.01.Angle PLC Announces Trading Update487Revenue for 2024 expected to be up 31%Lower cost base going into 2025 with a growing sales pipeline of opportunities GUILDFORD, SURREY / ACCESS Newswire / January 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY)...
► Artikel lesen
13.12.24Angle PLC Announces HER2 Presentation at SABCS329WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUMIndependent findings support ANGLE's HER2 assay development programmePotential for stratification of breast...
► Artikel lesen
15.11.24Angle stock surges as firm showcases new assay products7
15.11.24Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR219RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed to provide an optimised, easily implemented...
► Artikel lesen
15.11.24Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR225CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGLE...
► Artikel lesen
14.11.243 Ways Investors Angle To Profit From Trump's Next Four Years1
13.11.24ANGLE plc: ANGLE presents two posters at EACR237PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCETwo posters highlight the importance of epitope-independent CTC enrichment and molecular characterisation...
► Artikel lesen
11.11.24Angle notes use of Parsortix system in treatment resistance study-
11.11.24Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients292ANGLE plc ("the Company")DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIBThe addition of CTC-DNA analysis...
► Artikel lesen
Seite:  Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1